Jubilant Pharmova Ltd

Jubilant Pharmova Ltd

Jubilant Pharmova Ltd has scheduled a Board Meeting on November 13, 2026, to consider and approve the unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026.

Jubilant Pharmova Ltd

Jubilant Pharmova Ltd has published a newspaper advertisement in Financial Express and Hindustan & Jansatta regarding a special window for re-lodging transfer requests of physical shares and KYC updation and dematerialization of physical share certificates.

Jubilant Pharmova Ltd

Jubilant Pharmova Ltd has published newspaper advertisements regarding the completion of dispatch of notice of Postal Ballot, as per Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Jubilant Pharmova Ltd

Jubilant Pharmova Ltd has initiated a postal ballot process for shareholder approval through remote e-voting. The ballot is for a special resolution and the results will be announced within two working days after the conclusion of the e-voting period.

Jubilant Pharmova Ltd

Jubilant Pharmova Ltd has announced that India Ratings and Research Pvt Ltd has assigned a credit rating of IND AA+/Stable to the company's proposed non-convertible debentures worth ₹1,400 crore.

Jubilant Pharmova Ltd

Jubilant Pharmova Ltd has announced that ICRA Limited has assigned a credit rating of [ICRA]AA+ (Stable) to its proposed non-convertible debentures worth ₹1,400 crore.

Jubilant Pharmova Ltd

Jubilant Pharmova Ltd has announced the issuance of up to 80,000 non-convertible debentures on a private placement basis, aggregating up to ₹800 crore, and seeking members' authorization for issuance of non-convertible debt securities on a private placement basis for an aggregate amount not exceeding ₹2,500 crore.

Jubilant Pharmova Ltd

Jubilant Pharmova Ltd has announced the issuance of up to 80,000 secured/unsecured non-convertible debentures on a private placement basis, aggregating up to ₹800 crore, subject to regulatory approvals.

Jubilant Pharmova Ltd

Jubilant Pharmova Ltd announces investment of CAD 94.5 million to double production capacity of its flagship product, RUBY-FILL, through its subsidiary Jubilant Draximage Inc. The Government of Canada will provide a financial support of CAD 23.8 million to this project.

Jubilant Pharmova Ltd

Jubilant Pharmova Ltd's board meeting on October 12, 2026, will consider and approve raising funds through Non-Convertible Debentures (NCDs) and/or other securities, and seek shareholders' approval as required.

Jubilant Pharmova Ltd

Jubilant Pharmova Ltd has submitted a compliance certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018 for the quarter ended September 30, 2026, confirming the dematerialization of securities.

Jubilant Pharmova Ltd

Jubilant Pharmova Ltd has closed its trading window for insiders from October 1, 2026, until 48 hours after the declaration of unaudited financial results for the quarter ended September 30, 2026.

Jubilant Pharmova Ltd

Jubilant Pharmova Ltd has withheld the final dividend for FY 2025-26 for shareholders who have not submitted KYC documents, and has sent a specimen letter to them to update their details.

Jubilant Pharmova Ltd

Jubilant Pharmova Ltd has received a Show Cause Notice from the Assistant Commissioner of Commercial taxes (Enforcement)-4, Mysore, proposing a demand of GST, interest, and penalty for the Financial Year 2022-2023. The company intends to file a detailed reply with documentary evidence and expects no financial or operational impact.

Jubilant Pharmova Ltd

Jubilant Pharmova Ltd has published a newspaper advertisement regarding a special window for re-lodging transfer requests of physical shares and KYC updation and dematerialization of physical share certificates.

Jubilant Pharmova Ltd

Jubilant Pharmova Ltd has received a Show Cause Notice from the Joint Commissioner, CGST Division, Roorkee, proposing a demand of GST, interest, and penalty for FY 2020-21 and 2021-22. The company plans to file a detailed reply and expects no financial or operational impact.

Jubilant Pharmova Ltd

Jubilant Pharmova Ltd held its 48th Annual General Meeting (AGM) on August 26, 2026, through video conferencing. All resolutions were passed with the requisite majority. The meeting was attended by 86 members, representing 7,07,21,051 equity shares. The company's financial and operational performance for the year was discussed.

Jubilant Pharmova Ltd

Jubilant Pharmova Ltd held its 48th Annual General Meeting (AGM) on August 26, 2026, through Video Conferencing (VC). All resolutions were passed with the requisite majority. The meeting was attended by 86 members representing 7,07,21,051 equity shares. The company has uploaded the proceedings, voting results, and scrutinizer's report on its website and National Securities Depositories Limited.

Jubilant Pharmova Ltd

Jubilant Pharmova Ltd announces USFDA approval for its new Isolator based fill and finish line, Line 3 at Contract manufacturing facility, Spokane, U.S.A.

Jubilant Pharmova Ltd

Jubilant Pharmova Ltd's shareholders have approved the re-appointment of Mr. Priyavrat Bhartia as Managing Director and Mr. Arjun Shanker Bhartia as Joint Managing Director, with both resolutions being passed with a 100% majority.